Real-World Safety Profile of Generic Palbociclib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Prospective Observational Study in Iraq
June 2026
in “
Journal of cancer research updates
”
Studysummary This study conducted in an Iraqi oncology setting found generic Palbociclib to have a safety profile consistent with previous data, with observed side effects including high rates of neutropenia and anemia, particularly among patients receiving it with Fulvestrant.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on neoplasiaresearch.com →